Novartis Completes US Expansion Plan with New North Carolina Facility

Novartis completed its US expansion plan on April 30, marking the final build in a $23 billion multi-site investment program. The last new facility, located in North Carolina, will manufacture active pharmaceutical ingredients (API), with production slated to begin in the coming months.

The North Carolina site adds to Novartis's growing U.S. manufacturing footprint, which also includes investments in research and development infrastructure. The company has positioned the expansion as a strategic move to reduce reliance on overseas contract manufacturers and capture more of the pharmaceutical value chain in the world's largest drug market.

With the $23 billion program now fully deployed across multiple U.S. sites, NVS is positioned to benefit from the secular trend toward onshored pharmaceutical production — a dynamic accelerated by supply chain vulnerabilities exposed during COVID and reinforced by policy incentives for domestic drug manufacturing. The North Carolina facility's focus on API production directly addresses a critical bottleneck in the U.S. drug supply chain.

Related Stocks

• NVS